Literature DB >> 35704275

Amine-weighted chemical exchange saturation transfer magnetic resonance imaging in brain tumors.

Nicholas S Cho1,2,3,4, Akifumi Hagiwara1,2, Jingwen Yao1,2,3, David A Nathanson5, Robert M Prins6, Chencai Wang1,2, Catalina Raymond1,2, Brandon R Desousa5, Ajit Divakaruni5, Danielle H Morrow5, Phioanh L Nghiemphu7,8, Albert Lai7,8, Linda M Liau6, Richard G Everson6, Noriko Salamon2, Whitney B Pope2, Timothy F Cloughesy7,8, Benjamin M Ellingson1,2,3,6,8,9.   

Abstract

Amine-weighted chemical exchange saturation transfer (CEST) magnetic resonance imaging (MRI) is particularly valuable as an amine- and pH-sensitive imaging technique in brain tumors, targeting the intrinsically high concentration of amino acids with exchangeable amine protons and reduced extracellular pH in brain tumors. Amine-weighted CEST MRI contrast is dependent on the glioma genotype, likely related to differences in degree of malignancy and metabolic behavior. Amine-weighted CEST MRI may provide complementary value to anatomic imaging in conventional and exploratory therapies in brain tumors, including chemoradiation, antiangiogenic therapies, and immunotherapies. Continual improvement and clinical testing of amine-weighted CEST MRI has the potential to greatly impact patients with brain tumors by understanding vulnerabilities in the tumor microenvironment that may be therapeutically exploited.
© 2022 John Wiley & Sons Ltd.

Entities:  

Keywords:  Amine CEST; Brain Tumor; CEST EPI; Glioblastoma; Treatment Response; pH Imaging

Year:  2022        PMID: 35704275     DOI: 10.1002/nbm.4785

Source DB:  PubMed          Journal:  NMR Biomed        ISSN: 0952-3480            Impact factor:   4.044


  1 in total

1.  Quantitative Chemical Exchange Saturation Transfer Imaging of Amide Proton Transfer Differentiates between Cerebellopontine Angle Schwannoma and Meningioma: Preliminary Results.

Authors:  Hirofumi Koike; Minoru Morikawa; Hideki Ishimaru; Reiko Ideguchi; Masataka Uetani; Takeshi Hiu; Takayuki Matsuo; Mitsuharu Miyoshi
Journal:  Int J Mol Sci       Date:  2022-09-05       Impact factor: 6.208

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.